

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7865038

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	ASSIGNMENT		
CONVEYING PARTY DATA			
Name			Execution Date
SHANDONG LUYE PHARMACEUTICAL CO., LTD.			03/24/2023
RECEIVING PARTY DATA			
Name:	GENEORA PHARMA (SHIJIAZHUANG) CO., LTD.		
Street Address:	5TH FLOOR, RUNJIANG HEADQUARTERS INTERNATIONAL BUILDING, NO. 455 YUHUA EAST ROAD		
Internal Address:	SHIJIAZHUANG HIGH-TECH ZONE		
City:	SHIJIAZHUANG CITY, HEBEI PROVINCE		
State/Country:	CHINA		
Postal Code:	050000		
PROPERTY NUMBERS Total: 1			
Property Type	Number		
Patent Number:	9220782		
CORRESPONDENCE DATA			
Fax Number:	(609)799-7655		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	609-799-7600		
Email:	jeffrey.liao@luye.com		
Correspondent Name:	JEFFREY ZHI YANG LIAO		
Address Line 1:	502 CARNEGIE CENTER DRIVE, SUITE 100		
Address Line 4:	PRINCETON, NEW JERSEY 08540		
ATTORNEY DOCKET NUMBER:	851165.408C1		
NAME OF SUBMITTER:	JEFFREY ZHI YANG LIAO		
SIGNATURE:	/Jeffrey Zhi Yang Liao/		
DATE SIGNED:	03/24/2023		
Total Attachments: 3			
source=02. LY03003 US9220782 Patent Assignment - Shandong Luye to Jiaao#page1.tif			
source=02. LY03003 US9220782 Patent Assignment - Shandong Luye to Jiaao#page2.tif			
source=02. LY03003 US9220782 Patent Assignment - Shandong Luye to Jiaao#page3.tif			

PATENT ASSIGNMENT

WHEREAS, Luping Zhang, the inventor (the "Inventor"), has made certain inventions or discoveries (or both) as set forth in Letters Patent of the United States of America, entitled LONG ACTING SUSTAINED-RELEASE FORMULATION CONTAINING DOPAMINE RECEPTOR AGONIST AND THE PREPARATION METHOD THEREOF bearing U.S. Patent No. 9,220,782 issued on December 29, 2015 (the "Patent");

WHEREAS, Shandong Luye Pharmaceutical Co., Ltd., a limited liability company organized and existing under the laws of the People's Republic of China ("China"), and having a principal place of business at No. 9, Baoyuan Road, Laishan District, Yantai, Shandong Province, 264003, China, and, together with its successors and assigns, hereinafter called "Assignor", has acquired the entire right, title and interest in and to the Patent from the Inventor as reflected in a Patent Assignment recorded in the United States Patent and Trademark Office at Reel/Frame: 019340/0802, and is willing to transfer such right, title and interest to Assignee (as hereinafter defined);

WHEREAS, Geneora Pharma (Shijiazhuang) Co., Ltd., a corporation organized under the laws of China, with a principal place of business at 5th Floor, Runjiang Headquarters International Building, No. 455 Yuhua East Road, Shijiazhuang High-Tech Zone, Shijiazhuang City, Hebei Province, 050000, China ("Geneora"), and, together with its successors and assigns, hereinafter called "Assignee", is desirous of acquiring the title, rights, benefits and privileges hereinafter recited;

NOW THEREFORE, for valuable consideration furnished by Assignee, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby, without reservation:

1. Assigns, transfers and conveys to Assignee the entire right, title and interest in and to said inventions and discoveries, said Letters Patent of the United States of America, any and all other applications for Letters Patent on said inventions and discoveries in any and all countries, including all PCT, national stage, non-provisional, continuation, divisional, reissue, renewal, and substitute applications based in whole or in part upon said inventions or discoveries, or upon said applications, and any and all Letters Patent, reissues and extensions of Letters Patent granted for said inventions and discoveries or upon said applications, and every priority right that is or may be predicated upon or arise from said inventions, said discoveries, said applications and said Letters Patent;

2. Authorizes Assignee to file patent applications in any or all countries and jurisdictions on any or all of said inventions and discoveries in our names or in the name of Assignee or otherwise as Assignee may deem advisable, under the Patent Cooperation Treaty, European Patent Convention, the laws of any country or jurisdiction, or otherwise;

3. Authorizes and requests the Director of the United States Patent and Trademark Office and the empowered officials of all other governments to issue or transfer all said Letters Patents to Assignee, as Assignee of the entire right, title and interest therein or otherwise as Assignee may direct;

4. Warrant that it has not knowingly conveyed to others any right in said inventions, discoveries, applications or patents or any license to use the same or to make, use or sell anything embodying or utilizing any of said inventions or discoveries; and that it has good right to assign the same to Assignee without any encumbrances;

5. Binds its legal representatives and assigns, as well as itself, to perform, upon Assignee's request and at Assignee's expense, but without additional consideration to it or them, all acts reasonably serving to assure that said inventions and discoveries, said patent applications and said Letters Patent shall be held and enjoyed by Assignee as fully and entirely as the same could have been held and enjoyed by it, its legal representatives and assigns as if this assignment had not been made; and particularly to execute and deliver to Assignee all lawful application documents, including petitions, specifications, and oaths, and all assignments, disclaimers, and lawful affidavits in form and substance as may be requested by Assignee; to communicate to Assignee all facts known to it relating to said inventions and discoveries or the history thereof; and to furnish Assignee with any and all documents, photographs, models, samples and other physical exhibits in its control or in the control of its heirs, legal representatives or assigns, which may be useful for establishing the facts of the conceptions, disclosures, and reduction to practice of said inventions and discoveries.

IN WITNESS WHEREOF, Shandong Luye Pharmaceutical Co., Ltd., through its authorized representative, has hereunto set its hands and signed its name.

[The rest of this page is left intentionally blank.]

2023.03.24
Date

Lifang Sun (Assignor)
Shandong Luye Pharmaceutical Co., Ltd.
By: Lifang Sun
Title: Vice President of Intellectual Property
Department

I declare that I was personally present and did see Lifang Sun, who is personally known to me to be the Vice President of the Intellectual Property Department of Shandong Luye Pharmaceutical Co., Ltd., duly sign and execute the same.

Date 2023.03.24

Signed at Yantai

Qingjing Xu
(Name of Witness)

Qingjing Xu
(Signature of Witness)

ACCEPTED:

Geneora Pharma (Shijiazhuang) Co., Ltd.

2023.03.24
Date

Shixu Li (Assignee)
(Signatory Signature)

Shixu Li
General Manager

(Assignee Signatory Name, Title)

I declare that I was personally present and did see Shixu Li, who is personally known to me to be the General Manager of Geneora Pharma (Shijiazhuang) Co., Ltd., duly sign and execute the same.

Date 2023.03.24

Signed at Yantai

Xuejie Li
(Name of Witness)

Xuejie Li
(Signature of Witness)